Bristol Myers Squibb completes acquisition of Karuna Therapeutics, Inc. to strengthen its neuroscience portfolio
Acquiring Company
Bristol Myers Squibb
Acquired Company
Karuna Therapeutics
PrincetonBostonManufacturingBiotechnologyProfessional ServicesHealth CareMedicalTherapeuticsPharmaceuticalLegalBiopharmaLaw EnforcementBiotechnologyHealth CareTherapeuticsBiopharmaDescription
Bristol Myers Squibb has successfully completed the acquisition of Karuna Therapeutics, Inc. This acquisition adds KarXT, an antipsychotic with a novel mechanism of action, and Karuna’s early-stage and pre-clinical pipeline to Bristol Myers Squibb’s portfolio, reinforcing its commitment to strengthening its growth profile in the latter half of the decade and beyond.
Quick answer
Bristol Myers Squibb is acquiring Karuna Therapeutics, announced March 18, 2024. Bristol Myers Squibb is based in Princeton, New Jersey, United States.
- How much did Bristol Myers Squibb pay for Karuna Therapeutics?
- The deal value was not disclosed.
- What does Bristol Myers Squibb do?
- Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
- Where are Bristol Myers Squibb and Karuna Therapeutics based?
- Bristol Myers Squibb is based in Princeton, New Jersey, United States. Karuna Therapeutics is based in Boston, Massachusetts, United States.
- Who are the decision-makers at Bristol Myers Squibb?
- Fundz holds 2 contacts at Bristol Myers Squibb. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Professional Services and Medical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Abbvie To Acquire Landos Biopharma, Further Strengthening Its Portfolio In Inflammatory And Autoimmune Diseases (March 25, 2024)
- Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform (February 26, 2024)
- Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline (April 10, 2024)
- Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction (March 25, 2024)
- Harmony Biosciences acquires Epygenix Therapeutics, Inc. to expand rare epilepsy franchise (April 30, 2024)
- Eli Lilly and Company acquires manufacturing facility from Nexus Pharmaceuticals to expand U.S. capacity (April 22, 2024)
Who to call at Bristol Myers Squibb, and when
When Bristol Myers Squibb changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Bristol Myers Squibb raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Bristol Myers Squibb, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Bristol Myers Squibb. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Bristol Myers Squibb makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Karuna Therapeutics?
Karuna Therapeutics was acquired by Bristol Myers Squibb, based in Princeton. The deal was reported on March 18, 2024. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol Myers Squibb is publicly traded (BMY) and operates in Manufacturing.
When did Bristol Myers Squibb acquire Karuna Therapeutics?
Bristol Myers Squibb's acquisition of Karuna Therapeutics was reported on March 18, 2024. Bristol Myers Squibb has successfully completed the acquisition of Karuna Therapeutics, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Karuna Therapeutics do?
Karuna Therapeutics, Inc. is a clinical-stage biotherapeutics company with a focus on developing innovative treatment options for patients with psychiatric and neurological conditions. It is privately held, operating in Biotechnology, and is based in Boston.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.